<code id='119E109E8A'></code><style id='119E109E8A'></style>
    • <acronym id='119E109E8A'></acronym>
      <center id='119E109E8A'><center id='119E109E8A'><tfoot id='119E109E8A'></tfoot></center><abbr id='119E109E8A'><dir id='119E109E8A'><tfoot id='119E109E8A'></tfoot><noframes id='119E109E8A'>

    • <optgroup id='119E109E8A'><strike id='119E109E8A'><sup id='119E109E8A'></sup></strike><code id='119E109E8A'></code></optgroup>
        1. <b id='119E109E8A'><label id='119E109E8A'><select id='119E109E8A'><dt id='119E109E8A'><span id='119E109E8A'></span></dt></select></label></b><u id='119E109E8A'></u>
          <i id='119E109E8A'><strike id='119E109E8A'><tt id='119E109E8A'><pre id='119E109E8A'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:4

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In